It has now been 14 weeks since the first IONIC patient began treatment. Blood analysis is done every four weeks and scans done every eight weeks, with the 16-week scans likely to be the first time we will know whether NOX66 boosts the efficacy of Opdivo. That is just two weeks from now.
What shareholders seem to have missed is that the IONIC trial does not need a control arm. Each patient is either unsuitable for Opdivo, or has just suffered disease progression while being treated with Opdivo or Keytruda. If there is any response at all, it will unequivocally be because of NOX66
- Forums
- ASX - By Stock
- NOX
- IONIC Update
IONIC Update, page-3
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $21.04M |
Open | High | Low | Value | Volume |
7.2¢ | 7.2¢ | 7.2¢ | $1.367K | 18.99K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14000 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 79000 | 0.063 |
1 | 100000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
0.080 | 100000 | 1 |
Last trade - 15.33pm 26/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |